NewNo. 013
Retatrutide
GLP-1 / GIP / glucagon triple receptor agonist
- Size
- 4 sizes
- HPLC
- 99.2%
- Lot
- 07022601
ALTA PEPTIDES supplies research peptides for laboratory use only. You must be at least 18 to enter.
By entering you agree these products are for research use only and not for human consumption.GLP-1 / GIP / glucagon / amylin quadruple agonist
Lot certificate published at release
Celltrion and SCOHIA PHARMA's quadruple agonist: one molecule designed to activate the GLP-1, GIP, glucagon and amylin receptors. Price and availability coming soon; register to hear first.
CT-G32, also coded SCO-940, is an experimental obesity and metabolic compound from Celltrion and Japan's SCOHIA PHARMA. It is a single molecule designed to switch on four hormone receptors at once: GLP-1, GIP, glucagon and amylin. Semaglutide acts on one of these, tirzepatide on two and retatrutide on three; CT-G32 is the first disclosed molecule built to act on all four.
The first results were presented at TIDES Europe in Amsterdam in November 2026, and all of them are from animals. In diet-induced obese rats, CT-G32 produced numerically greater weight loss than retatrutide at the same molar dose, with a smaller share of the weight lost coming from lean mass, and it lowered obesity-related high insulin. In monkeys it stayed in the blood long enough to support a once-weekly profile. The companies have not yet published the percentages or the amino-acid sequence. Our CT-G32 explainer covers the results, the timeline and what they do not show.
CT-G32 is coming soon to ALTA PEPTIDES. Price, vial size and release date will be confirmed here, together with the certificate of analysis for the first lot, before it goes on sale. Register below to be told first. Celltrion plans to ask the US FDA to begin human trials by February 2027; CT-G32 is not a licensed medicine anywhere, including the UK.
Every ALTA PEPTIDES compound ships against a published lot certificate. For CT-G32 that means identity by mass spectrometry and purity by HPLC, set against the structure once the developers publish it. Until then, treat any listing that claims a verified CT-G32 sequence with caution. Our guide to reading a certificate of analysis explains what to check.
The closest compound with a large body of published research is retatrutide, the GLP-1, GIP and glucagon triple agonist that CT-G32 was compared against in rats. ALTA PEPTIDES holds retatrutide research vials and the sealed retatrutide pen in UK stock, each with a published lot certificate. For the wider field, see our guides to amylin agonists and retatrutide.
NewNo. 013
GLP-1 / GIP / glucagon triple receptor agonist
NewNo. 014
Synedica pre-filled pen: 40 mg retatrutide, with needles